Results 81 to 90 of about 3,791 (213)

Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives

Journal of Gastroenterology and Hepatology, Volume 41, Issue 4, Page 1173-1190, April 2026.
ABSTRACT Pancreatic neuroendocrine tumors (PanNETs) are increasingly diagnosed, reflecting greater clinical awareness, improved imaging, and revised classification. This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and
Angelo Bruni, David Meacci, Roberto Falbo, Marco Fichera, Francesco Poggioli, Riccardo Casadei, Claudio Ricci, Leonardo Henry Eusebi   +7 more
wiley   +1 more source

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

BMC Gastroenterology, 2018
Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases.
Arthur J. A. T. Braat, Dik J. Kwekkeboom, Boen L. R. Kam, Jaap J. M. Teunissen, Wouter W. de Herder, Koen M. A. Dreijerink, Rob van Rooij, Gerard C. Krijger, Hugo W. A. M. de Jong, Maurice A. A. J. van den Bosch, Marnix G. E. H. Lam   +10 more
doaj   +1 more source

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu‐DOTA‐TATE: A post‐authorisation safety study

Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract A post‐authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine‐Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET) eligible for 177Lu‐DOTATATE treatment.
Johannes Hofland, Chiara Maria Grana, Martin O. Weickert, Andrew R. Moore, Tahir Shah, Vineet Prakash, Agnieszka Kolasińska‐Ćwikła, Wouter W. de Herder, Francesca Spada, Lingfei Xu, Ramon Fite, Yuan Wu, Jarosław B. Ćwikła   +12 more
wiley   +1 more source

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids

Journal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of lung and thymic carcinoids, based on recent developments and study results. These recommendations aim to provide practical recommendations for the diagnosis, treatment and follow‐up of these ...
Eric Baudin, Alice Durand, Wieneke Buikhuisen, Jaume Capdevila, Martyn Caplin, Christophe M. Deroose, Clarisse Dromain, Antongiulio Faggiano, Pier Luigi Filosso, Gregory Kaltsas, Marco Volante, Thomas Walter, Rocio Garcia‐Carbonero   +12 more
wiley   +1 more source

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Aim Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Wei Wang, Jiayuan Cui, Yuxuan Bo, Yuxuan Wang, Zhipeng Sun, Xin Guan, Baoan Hong, Ning Zhang   +7 more
wiley   +1 more source

Mausolate Complexes of the Alkaline Earth Metals

ChemistryEurope, Volume 4, Issue 3, March 2026.
Reliable chelation of Ra2+ for radionuclide therapy has long been a challenge, and the capacious and rigid mausolate ligand may offer a promising approach. We describe herein mausolate complexes with the chemically similar Ba2+, and other group 2 dications, including the introduction of functionalized derivatives. The rapid uptake of alkaline earth (Ae)
Jack F. Smart, Liam D. N. Krueckl, R. Quinn Schmidt, Leah Gajecki, Lindsey E. K. Frederiksen, Allen G. Oliver, David J. Berg, J. Scott McIndoe   +7 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

A case report of acute carcinoid heart failure during lutetium-177 dotatate–triapine treatment for well-differentiated neuroendocrine tumors

Frontiers in Oncology
IntroductionWell-differentiated neuroendocrine tumors (NETs) have a high indolent local progression rate when resistance develops to biologic or cytotoxic chemotherapy.
Aman Chauhan, Elise C Kohn, S Percy Ivy, Jill M Kolesar, Rakhi Modak, Susanne Arnold, Lowell Anthony, William E. Carson, Nathan R Shelman, Charles A Kunos   +9 more
doaj   +1 more source

Imaging-derived biomarkers from ⁶⁸Ga-DOTATOC PET/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with ¹⁷⁷Lu-DOTATATE. [PDF]

Cancer Imaging
Neuroendocrine tumors have increased in prevalence and diversity in recent years and are often diagnosed at metastatic stages. Compared with nonradioactive systemic treatment with somatostatin analogs, peptide receptor radionuclide therapy (PRRT) has ...
Raad S, Al-Fatlawi A, Wise CL, Fottner C, Schadmand-Fischer S, Schreckenberger M, Weber MM, Musholt TJ, Schroeder M, Miederer M.   +9 more
europepmc   +2 more sources

NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Journal of Nuclear Medicine, 2019
With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing.
T. Hope, Amanda Abbott, K. Colucci, D. Bushnell, Linda Gardner, W. S. Graham, Sheila Lindsay, D. Metz, D. Pryma, M. Stabin, J. Strosberg   +10 more
semanticscholar   +1 more source